Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 19 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

0%

0 of 18 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (13)
P 1 (2)
P 2 (2)
P 3 (1)

Trial Status

Completed18
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT00000639Not ApplicableCompletedPrimary

A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00000776Phase 2CompletedPrimary

Dexamethasone in Cryptococcal Meningitis

NCT02334670UnknownPrimary

Vietnam Cryptococcal Retention in Care Study Version 1.0

NCT00001017Phase 3CompletedPrimary

Comparison of Fluconazole and Amphotericin B in the Treatment of Brain Infections in Patients With AIDS

NCT00000708Not ApplicableCompletedPrimary

Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00012467Phase 2CompletedPrimary

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

NCT00002068Not ApplicableCompletedPrimary

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00002075Not ApplicableCompletedPrimary

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00002077Not ApplicableCompletedPrimary

An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002019Not ApplicableCompletedPrimary

Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

NCT00002305Not ApplicableCompletedPrimary

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

NCT00002294Not ApplicableCompletedPrimary

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients With AIDS

NCT00002113Not ApplicableCompletedPrimary

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

NCT00002306Not ApplicableCompletedPrimary

A Study of Fluconazole in the Treatment of Cryptococcal Meningitis in Patients Who Have Not Had Success With Amphotericin B

NCT00002040Not ApplicableCompletedPrimary

Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002074Not ApplicableCompletedPrimary

Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome

NCT00000677Phase 1CompletedPrimary

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

NCT00002076Not ApplicableCompletedPrimary

Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

NCT00002316Phase 1CompletedPrimary

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

Showing all 19 trials

Research Network

Activity Timeline